Using data from Cancer Therapeutics Evaluation Program-sponsored trials, factors such as Eastern Cooperative Oncology Group performance status, white blood cell count, creatinine clearance, albumin, aspartate aminotransferase, number of study drugs, presence of a biologic study drug, and dose relative to the maximum administered were identified as significant predictors of SDRT. This evidence concerns the gene ALB and cancer.